Keywords: wyeth, licensed, oxford, bio, antibody, 24m, deal

Wyeth licensed Oxford Bio antibody in $24M deal

Article | 10 March 2003

Print This

Wyeth has licensed exclusive development and marketing rights to ananticancer monoclonal antibody, either on its own or conjugated to a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in